Efficacy and Safety of HMR1766 in Patients With Fontaine Stage II Peripheral Arterial Disease

Inclusion Criteria: * Patient with stable symptoms of intermittent claudication of the lower extremities, secondary to chronic occlusive arterial disease from atherosclerosis etiology (symptoms present for 6 months or longer and not significantly changed within the past 3 months) * Initial claudication distance of 30 to 250 meters at screening constant workload treadmill test * Confirmation of underlying Peripheral Arterial Disease (PAD) at screening * Confirmation of symptom stability at randomization based on constant workload treadmill test performance * The patient must have optimal cardiovascular risk prevention and appropriate management of PAD, including clopidogrel at the dose of 75mg per day, during the study period Exclusion Criteria: * Patient participated in investigational clinical trials in the last month prior to screening * Pregnant or breast-feeding woman or woman without documented double birth control measures for at least 3 months prior to randomization * Symptoms of PAD before the age of 40 years * Recent initiations or discontinuation of treatment by vasoactive agents (e.g., pentoxifylline, berprost sodium, papverine, isoxsuprine, nylidrin, cyclandelate, and niacin derivatives). Patients treated by cilostazol within 3 months prior to screening will also be excluded * Recent lower-extremity surgical or endovascular arterial reconstructions or sympathectomy, or recent deep venous thrombosis * Recent occurrence of at least one of the following: acute myocardial infarction, unstable angina, coronary artery bypass graft, percutaenous coronary intervention, transient ischemic attack or stroke The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.